Evidence of use, before the buyer asks
A portfolio sells on demonstrated relevance. ClaimHit screens each asset against the live market, ranks what it finds by how strong the evidence actually is, and gives you charts you can put in the data room.
- —Evidence of use is the first question a buyer asks and the most expensive thing to produce.
- —Screening a whole portfolio manually is not viable, so assets get sold on claim language alone.
- —A list of company names without sources invites the buyer to discount everything on it.
What ClaimHit does about it
Screen the portfolio, not one patent
Send a batch and let each asset run through the same pipeline. Assets with live, evidenced targets separate themselves from the ones that do not.
Ranked by what was proven
Results are ordered by how much public evidence backs each one, with the sources listed so a buyer can open them. Anything that could not be confirmed is dropped, not shown with a caveat.
Charts for the data room
Hit Charts with the evidence behind every limitation, the artefact a buyer's counsel will actually read.
The long tail counts
Beyond the obvious names: component distributors, regulatory records, software catalogues and marketplaces are searched by field, so mid-market practitioners surface too.
Every result has to earn it. Candidates come from several models, live web search, forward citations and the registries for the field, but breadth only widens the net. Each one is still checked against real, citable evidence. See how →
Run one asset you have already sold, and compare what comes back to what you found by hand.
See a real Hit Report first.
A complete ClaimHit output on a published patent: the companies and products it reaches, the sources that confirmed each one, and a Hit Chart on the strongest hit. One email, no account.
Or watch a patent: we tell you when a new company appears for it.
Send us the list. We do the rest.
Paste the patent numbers. We reply with a proposal for the whole list within 24 hours on a business day, and run it on your go-ahead: the Hit Matrix, claim charts on the strongest hits, and the briefs. No software to learn.
Want to see it on one patent first? Run it as the pilot for $99 →
See who is using your patent.
The pilot is one patent: the full product search and one Hit Chart, with a 30-day money-back guarantee. No subscription, no card on file after that.